Form 4: Cogent Biosciences Director Matthew Ros Granted 44,700 Stock Options

Matthew Ros, a Director at Cogent Biosciences, Inc., was granted 44,700 stock options with an exercise price of $5.64, vesting on the earlier of June 4, 2026, or the 2026 Annual Meeting of Stockholders.

Summary

• Matthew Ros, a Director of Cogent Biosciences, Inc. (COGT), acquired 44,700 stock options.
• The transaction date for this grant was June 4, 2025.
• Each stock option has an exercise price of $5.64.
• The options will vest in full upon the earlier of the first anniversary of the grant date (June 4, 2026) or the date of the 2026 Annual Meeting of Stockholders.
• The expiration date for these stock options is June 4, 2035.
• Following this transaction, Matthew Ros beneficially owns 44,700 derivative securities directly.

Sentiment

Score: 7

Explanation: The document reports a standard equity grant to a director, which is generally viewed as a positive for aligning management interests with shareholders. It does not contain any negative financial or operational news.

Positives

• The grant of stock options to Director Matthew Ros aligns his financial interests with those of the shareholders, as the value of the options is tied to the company's stock performance.
• Equity compensation is a standard practice for attracting and retaining qualified directors, signaling commitment to long-term value creation.

Future Outlook

The vesting schedule of the granted stock options indicates a future incentive for the director, aligning their long-term commitment with the company's performance through at least the first anniversary of the grant or the 2026 Annual Meeting of Stockholders.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries as a form of long-term incentive compensation, designed to align the interests of board members with those of the company's shareholders.

Comparison to Industry Standards

• The grant of stock options to a director is a standard form of equity compensation across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• While specific comparable companies or projects are not detailed in this filing, such grants are generally benchmarked against peer group compensation practices to ensure competitiveness and alignment with shareholder interests.

Related Party Transactions

• The grant of stock options to Matthew Ros, a Director, constitutes a transaction with a related party. This is a standard form of director compensation and is disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, as the options gain value if the stock price increases.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The stock options will vest upon the earlier of June 4, 2026, or the date of the 2026 Annual Meeting of Stockholders.
• Following vesting, the director may choose to exercise the options at the specified exercise price before the expiration date of June 4, 2035.

Key Dates

Keywords

Cogent Biosciences, COGT, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Grant, Matthew Ros